{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(1)"],"submitter":["Reschke R"],"pubmed_abstract":["<h4>Background</h4>Immune checkpoint inhibitors have transformed melanoma therapy but frequently cause immune-related adverse events (irAEs), including colitis, that limit treatment. Reliable biomarkers predicting toxicity remain lacking.<h4>Methods</h4>In this retrospective, multicenter study, we analyzed pretreatment serum samples from 331 patients with metastatic melanoma treated with anti-CTLA-4 (ipilimumab), anti-PD-1 (pembrolizumab or nivolumab), or combination ipilimumab/nivolumab. IgG autoantibody reactivity against 832 human protein antigens, including autoimmune targets, cytokines, tumor-associated antigens, and cancer pathway proteins, was profiled using multiplex bead-based arrays. Statistical analysis (Significance Analysis of Microarrays and Cox regression) identified autoant"],"journal":["Journal for immunotherapy of cancer"],"pagination":["e013814"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12853468"],"repository":["biostudies-literature"],"pubmed_title":["Autoantibodies as predictors for immune-related adverse events in checkpoint inhibition therapy of metastatic melanoma."],"pmcid":["PMC12853468"],"pubmed_authors":["Hassel JC","Dummer R","Pfoehler C","Schulz C","Zucht HD","Gutjahr C","Hakim-Meibodi LE","Budde P","Weide B","Mangana J","Meier F","Richter J","Schulz-Knappe P","Reschke R","Wistuba-Hamprecht K","Brautigam M"],"additional_accession":[]},"is_claimable":false,"name":"Autoantibodies as predictors for immune-related adverse events in checkpoint inhibition therapy of metastatic melanoma.","description":"<h4>Background</h4>Immune checkpoint inhibitors have transformed melanoma therapy but frequently cause immune-related adverse events (irAEs), including colitis, that limit treatment. Reliable biomarkers predicting toxicity remain lacking.<h4>Methods</h4>In this retrospective, multicenter study, we analyzed pretreatment serum samples from 331 patients with metastatic melanoma treated with anti-CTLA-4 (ipilimumab), anti-PD-1 (pembrolizumab or nivolumab), or combination ipilimumab/nivolumab. IgG autoantibody reactivity against 832 human protein antigens, including autoimmune targets, cytokines, tumor-associated antigens, and cancer pathway proteins, was profiled using multiplex bead-based arrays. Statistical analysis (Significance Analysis of Microarrays and Cox regression) identified autoant","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-06-08T06:53:01.947Z","creation":"2026-06-08T03:14:42.54Z"},"accession":"S-EPMC12853468","cross_references":{"pubmed":["41592893"],"doi":["10.1136/jitc-2025-013814"]}}